In a novel approach to gene therapy, scientists funded by the National Eye Institute (NEI) report using gold nanoparticles and light to target specific cells in mouse retina.

The Kantorow Laboratory and research program have been continually funded by the NIH’s National Eye Institute for almost two decades.

Millions of Americans are progressively losing their sight as cells in their eyes deteriorate, but a new therapy developed by researchers at the University of California, Berkeley, could help prolong useful vision and delay total blindness.

Researchers at Case Western Reserve University have used a unique method to safely deliver gene therapy to fight a rare, but irreversible, genetic eye disorder known as Stargardt disease.

An artificial intelligence algorithm that can detect a potentially devastating cause of childhood blindness better than most human experts has been granted breakthrough status by the FDA.

Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced “dry” form of age-related macular degeneration.

Researchers at Joslin Diabetes Center have shown that a protein found in the eye can protect against and potentially treat diabetic eye disease.

Participants in a phase I/II clinical trial of a new enzyme-based treatment for severe dry eye disease experienced reduced signs of disease and discomfort, according to a paper in Translational Vision Science and Technology.

In studies with lab-grown human cells and in mice, Johns Hopkins Medicine researchers have found that an experimental drug may be twice as good at fighting vision loss as previously thought.

New research, which appears in the journal Proceedings of the Royal Society B, sheds light on how the damage in the brain caused by a stroke can lead to permanent vision impairment for approximately 265,000 Americans each year.